Abstract
Background Despite current matching efforts to identify optimal donor-recipient pairs in kidney transplantation, alloimmunity remains a major proponent of late transplant failure. While kidney allocation based on human leukocyte antigen (HLA) matching has markedly prolonged short-term graft survival, new data suggests that additional genetic parameters in donor-recipient matching could help improve the long-term outcomes. Here, we studied the impact of a recently discovered non-muscle myosin heavy chain 9 gene (MYH9) polymorphism on kidney allograft failure.
Methods We conducted a prospective observational cohort study, analyzing the DNA of 1,271 kidney donor-recipient transplant pairs from a single academic hospital for the MYH9 rs11089788 C>A polymorphism. The association of the MYH9 genotype with the risk of graft failure (primary outcome), biopsy-proven acute rejection (BPAR), and delayed graft function (DGF) (secondary outcomes) were determined.
Results The MYH9 polymorphism in the donor was not associated with 15-year death-censored kidney graft survival, whereas a trend was seen for the association between the MYH9 polymorphism in the recipient and graft failure (recessive model, P=0.056). Having the AA-genotype of the MYH9 polymorphism in recipients was associated with a higher risk of DGF (P=0.031) and BPAR (P=0.021), although the significance was lost after adjustment for potential confounders (P=0.15 and P=0.10, respectively). The combined presence of the MYH9 polymorphism in donor-recipient pairs was significantly associated with long-term kidney allograft survival (P=0.036), in which recipients with an AA-genotype receiving a graft with an AA-genotype had the worst outcome. After adjustment for covariates, this combined genotype remained significantly associated with 15-year death-censored kidney graft survival (HR 1.68, 95%-CI: 1.05 – 2.70, P=0.031).
Conclusions Our results reveal that recipients with an AA-genotype MYH9 polymorphism receiving a donor kidney with an AA-genotype, have a significantly elevated risk of graft failure after kidney transplantation.
Key points
In recipients, the MYH9 SNP was associated with delayed graft function and biopsy-proven acute rejection after kidney transplantation, although the significance was lost in multivariable analysis.
Presence of the MYH9 variant in both the donor and recipient significantly associated with long-term kidney allograft survival in multivariable analysis.
Our present findings suggests that matching donor-recipient transplant pairs based on the MYH9 polymorphism may attenuate the risk of graft loss.
Introduction
Despite the excellent short-term outcomes following solid organ transplantation, the long-term survival of kidney transplants has only negligibly improved in recent years.1 As a consequence, one out of five patients on the waitlist for kidney transplantation are candidates whose previous grafts failed.2 Maximizing the long-term outcomes of transplantation and preventing re-transplantation is, thus, paramount—not only for improving transplant recipients’ outcomes, but also for reducing waitlist pressures. Among the many drivers of late graft loss, alloimmunity, otherwise known as host anti-donor immune responses, remains to be the preeminent cause, notably, despite efforts to optimally match donor-recipient pairs.3,4 Recently, there are signs of a paradigm shift in the transplant field, with suggestions that allograft matching efforts should be updated to include novel genetic markers that better ensure long-term graft survival after kidney transplantation.5,6
In this regard, non-muscle myosin heavy chain II-A (MHCII-A), encoded by the myosin heavy chain 9 gene (MYH9), is a target of particular interest (Fig. 1A). Non-muscle MHCII-A is a ubiquitously expressed contractile protein involved in a myriad of processes ranging from cell division and adhesion to providing cytoskeletal support.7 Mutations in the MYH9 cause a complex set of disorders, known as MYH9-related diseases, that can affect every system in the body but are characterized by congenital thrombocytopenia, giant platelets and leucocyte inclusions.7 Although non-muscle MHCII-A is expressed by a variety of cell types, the podocyte lineage in particular, expressed high levels of this protein.7 Unsurprisingly, patients with MYH9-related disorders can clinically present with persistent proteinuria and a progressive decline in kidney function leading to end-stage kidney disease (ESKD).7,8 Subsequent studies linked common MYH9 polymorphisms to an increased risk of developing focal segmental glomerulosclerosis and non-diabetic ESKD.9,10 However, it is worthy to note that these associations were later shown to be dependent on a strong linkage disequilibrium of these MYH9 polymorphisms with variants in the apolipoprotein L1 gene (APOL1).7,11 Still, there are studies that show an association between MYH9 polymorphisms and chronic kidney disease (CKD) independently of linkage with APOL1, suggesting a potential role for MYH9 polymorphisms in the pathogenesis of ESKD.12,13
In a recent genome-wide linkage analysis, a significant association between the MYH9 rs11089788 polymorphism and kidney function was identified in a meta-analysis of three European populations.14 This MYH9 polymorphism was additionally found to be significantly associated with progressive loss of kidney function in other cohorts.13,15 Importantly, the associations between MYH9 rs11089788 and kidney function could not be explained by linkage disequilibrium with APOL1.15
Here, we investigated the impact of the recently discovered rs11089788 MYH9 polymorphism on long-term graft survival in the context of kidney transplantation (Fig. 1B). As a secondary outcome, we also assessed the association of this polymorphism with biopsy-proven acute rejection (BPAR) and delayed graft function (DGF).
Materials and Methods
Patient selection and study end-point
Patients receiving a single kidney transplantation at the University Medical Center Groningen (UMCG) in the Netherlands were recruited between March 1993 and February 2008. 1,271 of the 1,430 screened donor-recipient kidney transplant pairs were included in the current study as previously reported.16–21 Ethical approval for this study and the study protocol was given by the Institutional Review Board of the University Medical Center Groningen in Groningen, The Netherlands (Medical Ethical Committee 2014/077). The study protocol adhered to the Declaration of Helsinki. All subjects provided written informed consent. Reasons for exclusion of patients in this study were technical complications during surgery, lack of DNA, loss of follow-up, or re-transplantation at the time of recruitment. The primary endpoint of this study was long-term death-censored graft survival and the maximum follow-up period was 15 years. Graft failure was defined as the need for dialysis and/or re-transplantation. Secondary endpoints included: The occurrence of delayed graft function (DGF; described by the United Network for Organ Sharing as, “The need for at least one dialysis treatment in the first week after kidney transplantation,”) and biopsy-proven acute rejection (BPAR; based on the Banff ‘07 classification).
DNA extraction and MYH9 genotyping
Peripheral blood mononuclear cells from blood or splenocytes were obtained from both the donor and recipient. DNA isolation was done with a commercial kit according to the manufacturer’s instructions and stored at -80°C. Genotyping of the single nucleotide polymorphism (SNP) was performed using the Illumina VeraCode GoldenGate Assay kit as per the manufacturer’s instructions (Illumina, San Diego, CA, USA). We opted for the MYH9 rs11089788 C>A SNP, which has previously been associated with kidney function in healthy individuals and with disease progression in patients with CKD.13–15 Genotype clustering and calling were performed using BeadStudio Software (Illumina). The overall genotype success rate was 99.9% and only two samples were excluded from subsequent analyses because of a missing call rate.
Statistical analysis
SPSS software version 25 (SPSS Inc, Chicago, IL, USA) was used for our statistical analyses. Data are presented as the total number of patients with percentage [n (%)] for nominal variables, mean ± standard deviation for parametric variables, and median [IQR] for non-parametric variables. Differences among groups were tested with the Χ2 test for categorical variables or Student’s t-test for normally distributed variables, and the Mann-Whitney U-test for not-normally divided variables, respectively. The Log-rank test was used to test for differences in kidney allograft survival or rejection-free survival among the different genotypes. Logistic regression was used to assess the association of the MYH9 polymorphism with DGF. Univariable analysis was used to examine the association of the MYH9 polymorphism, recipient, donor, and transplant characteristics with BPAR as well as death-censored graft survival. Significant associations in univariable analyses were then assessed in a multivariable Cox regression. Two-tailed tests were regarded as significant at P < 0.05.
Results
Study population and determinants of graft failure
All patients who underwent a single kidney transplantation at the University Medical Center Groningen were recruited for this study (n=1,271). Baseline patient characteristics are shown in Table 1. During the mean study period of 6.2 years ± 4.2, 215 of 1,271 kidney transplant recipients (16.9%) developed graft failure. The main reason for graft failure was rejection (n = 126, containing acute rejection, transplant glomerulopathy, and chronic antibody-mediated rejection). Other causes for graft loss were surgical complications (n = 33), relapse of the original kidney disease (n = 16), other causes (n = 16), vascular disease (n = 12), and unknown cause (n = 12). In univariable analysis, DGF, recipient age, recipient blood type (AB vs others), donor type (living vs cadaveric), donor age, donor blood type (AB vs others), cold ischemia time, warm ischemia time, use of cyclosporin, and use of corticosteroids were all associated with graft failure (P < 0.05).
Distribution of the MYH9 polymorphism
The observed genotypic frequencies of the MYH9 SNP (rs11089788 C>A) did not differ between donors (n = 1269; CC, 25.0%; CA, 54.1%; AA, 20.9%) and recipients (n = 1269; CC, 25.7%; CA, 50.0%; AA, 24.3%) (P = 0.07). The distribution of the SNP was in Hardy−Weinberg equilibrium. Compared to the 1000 genomes project, the genotypic frequencies of the MYH9 polymorphism in recipients and donors were significantly different (P < 0.001).22 In both recipients and donors, the A-allele of the MYH9 SNP was more prevalent than the reported allele and genotype frequencies in the 1000 genomes project. The percentage of kidney allografts with DGF significantly differed based on the recipient MYH9 genotype (33.7% in CC, 29.6% in CA, 37.7% in AA, P = 0.041), but not for the donor MYH9 genotype (P = 0.93). For further analysis, heterozygotes (CA) and homozygotes (CC)-genotypes were combined into one group (CA/CC). In logistic regression, recipients carrying the AA-genotype of the MYH9 polymorphism had a significantly elevated risk of DGF (OR = 1.34 compared to CA/CC-genotypes; 95%-CI: 1.03 – 1.76; P = 0.031). In multivariable logistic regression, the AA-genotype of the MYH9 polymorphism in recipients was no longer significantly associated with the occurrence of DGF (OR =1.26 compared to CA/CC-genotypes; 95%-CI: 0.92 – 1.72; P = 0.15, Table 2). There was no difference in the overall BPAR frequency among the MYH9 genotypes in the donor (34.7% in CC, 33.0% in CA, 35.8% in AA, P = 0.69). In contrast, the distribution of the MYH9 polymorphism in the recipient showed a trend towards a higher risk of BPAR (31.6% in CC, 32.4% in CA, 39.3% in AA, P = 0.068, Fig. 2A). A significant association was found with BPAR when the AA-genotype of the MYH9 polymorphism in the recipient was compared to CA-and CC-genotypes (39.3% in AA versus 32.2% in CA/CC, P = 0.021, Fig. 2B). In multivariable Cox regression, the AA-genotype of the MYH9 polymorphism in recipients was no longer significantly associated with the occurrence of BPAR (HR = 1.22 compared to CA/CC-genotypes; 95%-CI: 0.97 – 1.54; P = 0.10, Table 3). In summary, although the AA-genotype of the MYH9 polymorphism in recipients was associated with DGF and BPAR, the significance was lost when correcting for potential confounders.
Long-term kidney graft survival based on the MYH9 genotypes
Kaplan–Meier survival analysis demonstrated no association between the MYH9 SNP in the recipient or the donor and death-censored kidney graft survival (Figure 3). However, a trend was seen for a heightened rate of graft failure in the recipients with an AA-genotype of the MYH9 polymorphism compared to CA- and CC-genotypes (graft loss: 33.2% in AA versus 24.1% in CA/CC, P = 0.056, Fig. 3B). Next, donor-recipient pairs were separated into four groups according to the presence or absence of the AA-genotype of the MYH9 polymorphism in the donor and recipient. Kaplan–Meier survival analyses showed a significant difference in graft failure rates among the four groups (P = 0.036, Fig. 4A). Intriguingly, the AA-genotype of the MYH9 polymorphism in the donor seemed to have a marginal positive impact on graft survival, whereas the AA-genotype in the recipient had a modest detrimental impact compared to donor-recipient pairs with the combined CC/CA-genotype. Recipients with an AA-genotype receiving a graft with an AA-genotype had the worst outcome. This combined genotype was identified in 6.3% of the donor-recipient pairs. Moreover, the significant association with graft failure increased when the combined AA-genotype of the MYH9 polymorphism in donor-recipient pairs was compared to the other groups (P = 0.011, Fig. 4B). The cumulative 15-year death-censored kidney allograft survival was 50.4% in this combined AA-genotype group and 74.9% in the reference group, respectively. These data suggest that matching donor-recipient pairs on the MYH9 polymorphism may impact long-term graft survival in kidney transplantation.
Regression analysis for the MYH9 polymorphism in donor-recipient pairs and graft failure
Finally, we investigated if the MYH9 variant in donor-recipient pairs is an independent risk factor for graft failure. In univariable analysis, the combined AA-genotype of the MYH9 SNP in donor-recipient pairs was associated with a hazard ratio of 1.78 (95%-CI: 1.13 – 2.79; P = 0.012) for graft failure after complete follow-up. Subsequently, multivariable analysis was performed to adjust for potential confounders, including donor and patient characteristics as well as transplant variables (Table 4). In these Cox regression analyses, the combined AA-genotype of the MYH9 SNP in donor-recipient pairs remained significantly associated with graft failure. Lastly, we performed a multivariable Cox regression analysis using all variables that were significantly associated with graft failure in univariable analysis (Table 5). In this model, the MYH9 SNP (rs11089788) in donor-recipient pairs, the occurrence of DGF, recipient age, and donor age were all significantly associated with graft loss. After adjustment, the hazard ratio for graft failure of the combined AA-genotype for the MYH9 SNP in donor-recipient pairs was 1.68 (95% CI: 1.05 – 2.70, P = 0.031). In conclusion, our results reveal that recipients with an AA-genotype of the MYH9 SNP receiving a kidney allograft with an AA-genotype have a significantly elevated risk of graft failure after kidney transplantation.
Discussion
A multitude of strategies can be pursued to improve the long-term outcomes after kidney transplantation, ranging from the development of novel drugs that can pull the brakes on allo-immune cascades, to the refinement of donor-recipient matching systems to minimize the severity of allograft recognition. Regarding allograft matching, HLA-centric systems remains the cornerstone of allocating kidney allografts—although a paradigm shift in the approach to donor-recipient matching is urgently needed.23 Genetic analyses in transplantation provides a particularly unique opportunity for the development of innovative strategies that can improve donor-recipient pairing and drive personalized medicine, in part by enabling individualized risk stratification.24,25 Presently, we report the impact of a recently discovered polymorphism in MYH9 on long-term kidney allograft survival. The key finding of our study is that recipients with an AA-genotype of the MYH9 rs11089788 variant receiving a kidney allograft with an AA-genotype of the same variant, have a significantly elevated risk of developing graft loss. In contrast, no association for the MYH9 polymorphism with long-term allograft survival was found in either the recipient or donor when assessed individually. Hence, our study provides evidence that matching recipients with donor kidneys based on the MYH9 polymorphism may well impact the risk of graft loss.
To our knowledge, our study is the first to show an association between this MYH9 variant and long-term graft survival after kidney transplantation. Specifically, we found that the combined AA-genotype in donor-recipient pairs nearly doubled the risk of graft failure. Genome-wide linkage analysis recently highlighted the MYH9 rs11089788 polymorphism as a top variant for kidney function in a meta-analysis of three European populations.14 In accordance with our results, the C-allele of the MYH9 rs11089788 polymorphism was consistently associated with better kidney function in healthy Europeans.14 Furthermore, in a Chinese cohort of IgA nephropathy patients, the A-allele of this variant was associated with hastened progression to kidney failure.13 Other groups, however, did not recapitulate an association between this MYH9 variant and kidney outcomes.26,27 In particular, Franceschini and colleagues found no relationship between the MYH9 rs11089788 polymorphism and kidney function or CKD in native Americans.27 Importantly, we found no relationship of this MYH9 variant in the recipient or the donor alone with death-censored kidney graft survival either. Our findings, thus, suggest that only donor-recipient interactions in MYH9 may lead to kidney function decline after renal transplantation.
The importance of the MYH9 for the kidney has been investigated by several group but remains controversial. Initial reports linked certain variants in the MYH9 to a greater risk of CKD.9,10 Later studies uncovered that this association was based on the strong linkage disequilibrium between MYH9 variants and variants in APOL1.7,11 Nonetheless, patients with rare mutations in MYH9 leading to MYH9-related diseases often present with signs of CKD and can develop ESKD.7,8 In line with these results, heterozygous mice with mutations in Myh9 manifest similar pathological kidney phenotypes as humans with MYH9-related diseases, including proteinuria, focal segmental glomerulosclerosis, and CKD.28 Intriguingly, Myh9 knockdown in zebrafish lead to the malformation and dysfunction of their glomeruli.29 More specifically, these zebrafish failed to correctly develop the glomerular capillary structure, lacking fenestration in the endothelial cells and having an absence or reduced number of mesangial cells together with irregular thickening of the glomerular basement membrane.29 Although kidney clearance experiments showed that the glomerular barrier function remained unaltered, glomerular filtration in these zebrafish was significantly reduced.29 Altogether, these findings attest a key role for MYH9 and non-muscle myosin heavy chain II-A in kidney development and physiology.
In humans, non-muscle myosin II-A, whose heavy chains are encoded by MYH9, is expressed in the podocytes, tubular cells, endothelial cells of the peritubular capillaries, interlobular arteries, and arterioles.30 A potential mechanism underpinning the association between MYH9 polymorphism and graft failure would likely be dependent on kidney-expressed non-muscle myosin heavy chain II-A. On the basis of our findings, however, alternative mechanisms may be more probable. Firstly, in the recipients a trend was found for the association between the MYH9 polymorphism and graft loss, while there was no association in the donor genotypes. Secondly, the AA-genotype of the MYH9 variant in the recipient, but not the donor, was associated with BPAR and DGF, although significance was lost after adjusting for potential confounders. Lastly, in the genotypic analysis of the donor-recipient pairs, the isolated donor AA-genotype was marginally protective while the isolated AA-genotype in the recipient had a modest detrimental effect on graft survival. Additional evidence supporting a systemic role of the MYH9 variant in determining kidney allograft outcomes is provided by case report of a patient with focal segmental glomerulosclerosis, where proteinuria rapidly recurred following a deceased donor kidney transplantation that therapeutically responded to plasmapheresis.31 Moreover, the fact that donor-recipient pairs with the combined AA-genotype of the MYH9 variant had the highest risk of graft loss in our population, suggests both donor-recipient interactions in MYH9 with perhaps a leading role for extra-renal expressed non-muscle myosin heavy chain II-A. A case report of two kidney transplants in pediatric patients suggested a similar donor-recipient MYH9 interaction.32
Overall, there are several limitations to our study that warrant consideration. First, our study design is observational in nature and thus cannot determine whether associations are based on causality. Therefore, we cannot exclude the possibility that the MYH9 rs11089788 variant is a tag SNP in the neighboring APOL1 to APOL6 region, justifying further investigation in this regard. Second, we investigated a single polymorphism in MYH9 and did not examine the impact of MYH9 haplotypes. Nevertheless, crucial strengths of our study were the analysis of the recently described MYH9 polymorphism in both donors and recipients, our large patient population, the long and complete follow-up, and the hard clinical endpoints.
In conclusion, we found that patients with an AA-genotype of the MYH9 rs11089788 variant receiving a donor kidney with the AA-genotype have an elevated risk of late graft loss. Considering the impact of this combined genotype, our findings imply donor-recipient interactions in MYH9 that negatively influence the long-term allograft survival of kidney allografts.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Disclosures
The authors declare that there are no competing interests to disclose.
Acknowledgments
The authors thank the members of the REGaTTA cohort (REnal GeneTics TrAnsplantation; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands): S. J. L. Bakker, J. van den Born, M. H. de Borst, H. van Goor, J. L. Hillebrands, B. G. Hepkema, G. J. Navis and H. Snieder. The illustrations of Figure 1 were made by Siawosh K. Eskandari.
Abbreviations
- APOL1
- Apolipoprotein L1 gene
- BPAR
- Biopsy-proven acute rejection
- CIT
- Cold ischemia time
- CKD
- Chronic kidney disease
- DBD
- Donation after circulatory death
- DCD
- Donation after brain death
- DGF
- Delayed graft function
- ESKD
- End-stage kidney disease
- HLA
- Human leukocyte antigen
- HR
- Hazard ratio
- MYH9
- Myosin heavy chain 9 gene
- PRA
- Panel-reactive antibody
- OR
- Odds ratio
- SNP
- Single-nucleotide polymorphism
- WIT
- Warm ischemia time